Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Feb 09, 2021 1:24pm
102 Views
Post# 32514438

RE:RE:TH is dead money

RE:RE:TH is dead money In fact, the percentage gains tend to be largest capturing the Phase 1 to in to Phase 2.  Immunomedics went up 4x between start of Phase 1 and 2. 

Spartrap wrote: Such a clueless thing to say, if you'll pardon me.
Please educate yourself on early Oncology potential, go read about EPIX for instance. Canadian Oncology company in mCRPC, a ten bagger in about 15 months, from promising pre-clinicals to mid phase I. You think they have published any human results yet? Well think again.
jeffm34 wrote: There is no reason to own TH at this price.  There is a major bull market in every stock not named Theratechnologies.  You've seen again in today's trading the effects of the disastrous financing deal. Take your TH money and go make a profit anywhere else. If you believe in TH long-term put a buy order in around 3.80-3.90 and hope things improve once the 14M shares are churned through. 




<< Previous
Bullboard Posts
Next >>